Paramount Considers Removing CEO Bob Bakish

The board is considering installing a committee of top executives to run the company on an interim basis as turmoil over sale talks deepens. 


 
Anglo Rejects BHP's $39 Billion Bid

The London-listed mining giant said the bid "significantly undervalues" the company, setting the stage for a potential bidding war. 


 
Exxon, Chevron Earnings Fall Back to Earth

The oil companies are still printing big profits, but their postpandemic run of record earnings is slowing down. 


 
U.S. Regulators Tie Tesla's Autopilot to More Than a Dozen Fatalities, Hundreds of Crashes

The NHTSA launched a new probe into the adequacy of a two-million vehicle recall in December, after discovering more crashes linked to the controversial technology. 


 
AMC Entertainment Sees Flat Revenue in Despite Fewer Film Releases

The movie-theater chain said the Hollywood writers and actors strikes from last year had dragged on box office returns. 


 
Warren Buffett's Real-Estate Firm Settles Antitrust Matter for $250 Million

The real-estate industry has now agreed to pay nearly $1 billion to settle anticompetitive allegations. 


 
Apollo Global to Buy U.S. Silica in $1.85 Billion Deal

U.S. Silica Holdings has agreed to be taken private by Apollo Global Management in a deal that gives the industrial minerals company an enterprise value of roughly $1.85 billion. 


 
Charter continues to shed internet subscribers, reflecting cable's growth woes

Charter lost more internet subscribers than expected in the first quarter as the cable industry's broadband growth challenges continued. 


 
Newell's stock rallies on revenue beat as it boosts margins and carries out restructuring plan

The parent company of Rubbermaid, Sharpie, Mr. Coffee, Elmer's glue and more said it lost $9 million, or 2 cents a share in the first quarter, compared to a loss of $102 million, or 25 cents a share, in the year-ago period. 


 
AbbVie's first-quarter results top expectations as arthritis drugs fuel growth

AbbVie on Friday reported first-quarter results that beat expectations even as sales of its blockbuster autoimmune drug Humira continued to fall.


(END) Dow Jones Newswires

04-26-24 1915ET